NSEI:VIMTALABS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vimta Labs Limited provides contract research and testing services in India and internationally. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Vimta Labs's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VIMTALABS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.1%

VIMTALABS

-4.3%

IN Life Sciences

1.4%

IN Market


1 Year Return

27.3%

VIMTALABS

61.6%

IN Life Sciences

2.2%

IN Market

Return vs Industry: VIMTALABS underperformed the Indian Life Sciences industry which returned 61.9% over the past year.

Return vs Market: VIMTALABS exceeded the Indian Market which returned 2.8% over the past year.


Shareholder returns

VIMTALABSIndustryMarket
7 Day-2.1%-4.3%1.4%
30 Day21.4%-1.1%5.6%
90 Day48.6%26.5%8.5%
1 Year27.3%27.3%62.5%61.6%4.0%2.2%
3 Year8.7%6.5%163.2%158.7%-0.5%-5.3%
5 Year87.5%81.8%158.5%148.5%41.6%31.1%

Price Volatility Vs. Market

How volatile is Vimta Labs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vimta Labs undervalued compared to its fair value and its price relative to the market?

29.07x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: VIMTALABS (₹136.9) is trading above our estimate of fair value (₹88.4)

Significantly Below Fair Value: VIMTALABS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VIMTALABS is good value based on its PE Ratio (29.1x) compared to the IN Life Sciences industry average (40.1x).

PE vs Market: VIMTALABS is poor value based on its PE Ratio (29.1x) compared to the Indian market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VIMTALABS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VIMTALABS is good value based on its PB Ratio (1.7x) compared to the IN Life Sciences industry average (1.8x).


Next Steps

Future Growth

How is Vimta Labs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vimta Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vimta Labs performed over the past 5 years?

12.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VIMTALABS has high quality earnings.

Growing Profit Margin: VIMTALABS's current net profit margins (5.5%) are lower than last year (7.3%).


Past Earnings Growth Analysis

Earnings Trend: VIMTALABS's earnings have grown by 12.2% per year over the past 5 years.

Accelerating Growth: VIMTALABS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: VIMTALABS had negative earnings growth (-25.7%) over the past year, making it difficult to compare to the Life Sciences industry average (4.5%).


Return on Equity

High ROE: VIMTALABS's Return on Equity (5.8%) is considered low.


Next Steps

Financial Health

How is Vimta Labs's financial position?


Financial Position Analysis

Short Term Liabilities: VIMTALABS's short term assets (₹981.5M) exceed its short term liabilities (₹531.1M).

Long Term Liabilities: VIMTALABS's short term assets (₹981.5M) exceed its long term liabilities (₹145.1M).


Debt to Equity History and Analysis

Debt Level: VIMTALABS's debt to equity ratio (8.7%) is considered satisfactory.

Reducing Debt: VIMTALABS's debt to equity ratio has increased from 4.9% to 8.7% over the past 5 years.

Debt Coverage: VIMTALABS's debt is well covered by operating cash flow (230.8%).

Interest Coverage: VIMTALABS's interest payments on its debt are well covered by EBIT (11.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Vimta Labs's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VIMTALABS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIMTALABS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VIMTALABS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIMTALABS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: VIMTALABS is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VIMTALABS's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Harita Vasireddi (46 yo)

7.25yrs

Tenure

₹13,440,000

Compensation

Ms. Harita Vasireddi, B. Pharm, MBA (USA) has been the Managing Director of Vimta Labs Ltd. since July 15, 2013 and serves as its Whole Time Director. She was a Member of Scientific Advisory Board at Vimta ...


CEO Compensation Analysis

Compensation vs Market: Harita's total compensation ($USD182.06K) is above average for companies of similar size in the Indian market ($USD54.90K).

Compensation vs Earnings: Harita's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Harita Vasireddi
MD & Whole Time Director7.25yrs₹13.44m0.76%
₹ 22.9m
Amit Pathak
Chief Financial Officer1.75yrs₹3.94mno data
V. Vungal
Executive Director of Operations & Executive Director29.92yrs₹13.44m8.04%
₹ 242.1m
Sujani Vasireddi
GM of Commercial2.17yrs₹2.30mno data
Suresh Kumar
President1.08yrsno datano data
Srinivas Puppala
Vice President of Human Resources1.75yrsno datano data
Jagadeesh Kodali
Head of Food Division & Associate VP of Food Division4.75yrsno datano data

2.2yrs

Average Tenure

45yo

Average Age

Experienced Management: VIMTALABS's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Harita Vasireddi
MD & Whole Time Director7.25yrs₹13.44m0.76%
₹ 22.9m
V. Vungal
Executive Director of Operations & Executive Director29.92yrs₹13.44m8.04%
₹ 242.1m
Sivalinga Vasireddi
Non Executive Chairmanno datano data16.28%
₹ 489.9m
Kanury Rao
Member of Scientific Advisory Boardno datano datano data
Satya Neerukonda
Executive Director1.25yrs₹7.69mno data
Pankaj Shah
Member of Scientific Advisory Boardno datano datano data
Yalamanchili Rani
Independent Non-Executive Director2.83yrs₹150.00kno data
Gutta Rao
Independent Non-Executive Director1.42yrs₹130.00kno data
Sanjay Dave
Independent Non-Executive Director1.42yrs₹100.00kno data
Yadagiri Pendri
Additional Non-Executive Independent Director0.17yrno datano data

1.4yrs

Average Tenure

64.5yo

Average Age

Experienced Board: VIMTALABS's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vimta Labs Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vimta Labs Limited
  • Ticker: VIMTALABS
  • Exchange: NSEI
  • Founded: 1984
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹3.010b
  • Shares outstanding: 22.11m
  • Website: https://www.vimta.com

Number of Employees


Location

  • Vimta Labs Limited
  • Plot Nos. 141/2 & 142, IDA, Phase II
  • Cherlapally
  • Hyderabad
  • 500051
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524394BSE (Mumbai Stock Exchange)YesEquity SharesININRJan 2002
VIMTALABSNSEI (National Stock Exchange of India)YesEquity SharesININRJan 2002

Biography

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers laboratory, food and water testing and analysis, preclinical and clinical research, biolo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/25 12:30
End of Day Share Price2020/10/23 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.